Fig. 3From: Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysisSummarizing figure of the meta-analysis comparing CRRM and CPI in BRCA1/2 carriers. CBC, contralateral breast cancer; OS, overall survival; BCSS, breast-cancer specific survival; RR, risk ratio; gBRCA1/2m, germline BRCA1/2 mutationBack to article page